Evidence map›Paper›PMID 33616474›Full record

ArticleHuman vaccines & immunotherapeutics2021

Polymeric nanoparticles containing rapamycin and autoantigen induce antigen-specific immunological tolerance for preventing vitiligo in mice.

Xia Zhang, Daji Liu, Minghong He, Mao Lin, Caixia Tu, Baoxiang Zhang

Open access · bronzeAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. The role of regulatory T cells in vitiligo and therapeutic advances: a mini-review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024
    Review
  9. Review
  10. Review
  11. Nanotargeted Delivery of Immune Therapeutics in Type 1 Diabetes.Advanced materials (Deerfield Beach, Fla.) · 2023
    Article
  12. Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art.International journal of molecular sciences · 2023
    Review
  13. Biomaterial Strategies for Selective Immune Tolerance: Advances and Gaps.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Xia ZhangDepartment of Dermatology, Weifang Yidu Central Hospital, Qingzhou, Shandong, China.
Daji LiuDepartment of Rheumatology, Weifang Yidu Central Hospital, Qingzhou, Shandong, China.
Minghong HeDepartment of Respiratory Medicine, Weifang Yidu Central Hospital, Qingzhou, Shandong, China.
Mao LinDepartment of Dermatology, Chongqing Chinese Medicine Hospital, Chongqing, China.
Caixia TuDepartment of Dermatology, The 2nd Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Baoxiang ZhangDepartment of Dermatology, Weifang Yidu Central Hospital, Qingzhou, Shandong, China.
Yidu Central Hospital of Weifang · CNDalian Medical University · CNFirst People's Hospital of Chongqing · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitiligo is an autoimmune disease in which pigment is lost in patches of the skin. CD4

Indexed as

NanoparticlesVitiligoAnimalsAutoantigensDendritic CellsMiceSirolimusAutoantigensSirolimusNanoparticlesrapamycintoleranceTregsvitiligo

Identifiers

PMID33616474
PMCPMC8189063
OpenAlexW3132157845

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.